Dose escalation and expansion cohorts in patients with advanced breast cancer in a Phase I study of the CDK7-inhibitor samuraciclib

Samuraciclib is a selective oral CDK7-inhibitor. A multi-modular, open-label Phase I study to evaluate safety and tolerability of samuraciclib in patients with advanced malignancies was designed (ClinicalTrials.gov: NCT03363893). Here we report results from dose escalation and 2 expansion cohorts: M...

Celý popis

Uložené v:

Podrobná bibliografia
Vydané v:	Nature communications Ročník 14; číslo 1; s. 4444 - 10
Hlavní autori:	Coombes, R. C., Howell, Sacha, Lord, Simon R., Kenny, Laura, Mansi, Janine, Mitri, Zahi, Palmieri, Carlo, Chap, Linnea I., Richards, Paul, Gradishar, William, Sardesai, Sagar, Melear, Jason, O’Shaughnessy, Joyce, Ward, Patrick, Chalasani, Pavani, Arkenau, Tobias, Baird, Richard D., Jeselsohn, Rinath, Ali, Simak, Clack, Glen, Bahl, Ashwani, McIntosh, Stuart, Krebs, Matthew G.
Médium:	Journal Article
Jazyk:	English
Vydavateľské údaje:	London Nature Publishing Group UK 24.07.2023 Nature Publishing Group Nature Portfolio
Predmet:	13/95 38/23 631/67/1059/153 692/308/153 692/4028/67/1347 Administration, Oral Anticancer properties Antitumor agents Biopsy Breast cancer Cancer therapies Cyclin-dependent kinase 4 Cyclin-Dependent Kinase Inhibitor Proteins Cyclin-Dependent Kinases Diarrhea Disease control DNA-directed RNA polymerase Enzyme Inhibitors ErbB-2 protein Fulvestrant Humanities and Social Sciences Humans Inhibitors Lymphocytes Malignancy Modules multidisciplinary Oral administration Patients Pharmacodynamics Pharmacokinetics RNA polymerase RNA polymerase II Safety Science Science (multidisciplinary) Solid tumors Substrates Triple Negative Breast Neoplasms Tumors Vomiting
ISSN:	2041-1723, 2041-1723
On-line prístup:	Získať plný text
Tagy:	Pridať tag Žiadne tagy, Buďte prvý, kto otaguje tento záznam!

Abstract	Samuraciclib is a selective oral CDK7-inhibitor. A multi-modular, open-label Phase I study to evaluate safety and tolerability of samuraciclib in patients with advanced malignancies was designed (ClinicalTrials.gov: NCT03363893). Here we report results from dose escalation and 2 expansion cohorts: Module 1A dose escalation with paired biopsy cohort in advanced solid tumor patients, Module 1B-1 triple negative breast cancer (TNBC) monotherapy expansion, and Module 2A fulvestrant combination in HR+/HER2− breast cancer patients post-CDK4/6-inhibitor. Core study primary endpoints are safety and tolerability, and secondary endpoints are pharmacokinetics (PK), pharmacodynamic (PD) activity, and anti-tumor activity. Common adverse events are low grade nausea, vomiting, and diarrhea. Maximum tolerated dose is 360 mg once daily. PK demonstrates dose proportionality (120 mg-480 mg), a half-life of approximately 75 hours, and no fulvestrant interaction. In dose escalation, one partial response (PR) is identified with disease control rate of 53% (19/36) and reduction of phosphorylated RNA polymerase II, a substrate of CDK7, in circulating lymphocytes and tumor tissue. In TNBC expansion, one PR (duration 337 days) and clinical benefit rate at 24 weeks (CBR) of 20.0% (4/20) is achieved. In combination with fulvestrant, 3 patients achieve PR with CBR 36.0% (9/25); in patients without detectable TP53-mutation CBR is 47.4% (9/19). In this study, samuraciclib exhibits tolerable safety and PK is supportive of once-daily oral administration. Clinical activity in TNBC and HR+/HER2-breast cancer post-CDK4/6-inhibitor settings warrants further evaluation. Pre-clinical studies have demonstrated the anti-tumor activity of selective inhibitors of CDK7, including samuraciclib. Here the authors report the results from dose escalation and two expansion cohorts in patients with breast cancer of a multi-modular Phase I clinical trial of samuraciclib as anti-cancer treatment.
AbstractList	Samuraciclib is a selective oral CDK7-inhibitor. A multi-modular, open-label Phase I study to evaluate safety and tolerability of samuraciclib in patients with advanced malignancies was designed (ClinicalTrials.gov: NCT03363893). Here we report results from dose escalation and 2 expansion cohorts: Module 1A dose escalation with paired biopsy cohort in advanced solid tumor patients, Module 1B-1 triple negative breast cancer (TNBC) monotherapy expansion, and Module 2A fulvestrant combination in HR+/HER2- breast cancer patients post-CDK4/6-inhibitor. Core study primary endpoints are safety and tolerability, and secondary endpoints are pharmacokinetics (PK), pharmacodynamic (PD) activity, and anti-tumor activity. Common adverse events are low grade nausea, vomiting, and diarrhea. Maximum tolerated dose is 360 mg once daily. PK demonstrates dose proportionality (120 mg-480 mg), a half-life of approximately 75 hours, and no fulvestrant interaction. In dose escalation, one partial response (PR) is identified with disease control rate of 53% (19/36) and reduction of phosphorylated RNA polymerase II, a substrate of CDK7, in circulating lymphocytes and tumor tissue. In TNBC expansion, one PR (duration 337 days) and clinical benefit rate at 24 weeks (CBR) of 20.0% (4/20) is achieved. In combination with fulvestrant, 3 patients achieve PR with CBR 36.0% (9/25); in patients without detectable TP53-mutation CBR is 47.4% (9/19). In this study, samuraciclib exhibits tolerable safety and PK is supportive of once-daily oral administration. Clinical activity in TNBC and HR+/HER2-breast cancer post-CDK4/6-inhibitor settings warrants further evaluation.Samuraciclib is a selective oral CDK7-inhibitor. A multi-modular, open-label Phase I study to evaluate safety and tolerability of samuraciclib in patients with advanced malignancies was designed (ClinicalTrials.gov: NCT03363893). Here we report results from dose escalation and 2 expansion cohorts: Module 1A dose escalation with paired biopsy cohort in advanced solid tumor patients, Module 1B-1 triple negative breast cancer (TNBC) monotherapy expansion, and Module 2A fulvestrant combination in HR+/HER2- breast cancer patients post-CDK4/6-inhibitor. Core study primary endpoints are safety and tolerability, and secondary endpoints are pharmacokinetics (PK), pharmacodynamic (PD) activity, and anti-tumor activity. Common adverse events are low grade nausea, vomiting, and diarrhea. Maximum tolerated dose is 360 mg once daily. PK demonstrates dose proportionality (120 mg-480 mg), a half-life of approximately 75 hours, and no fulvestrant interaction. In dose escalation, one partial response (PR) is identified with disease control rate of 53% (19/36) and reduction of phosphorylated RNA polymerase II, a substrate of CDK7, in circulating lymphocytes and tumor tissue. In TNBC expansion, one PR (duration 337 days) and clinical benefit rate at 24 weeks (CBR) of 20.0% (4/20) is achieved. In combination with fulvestrant, 3 patients achieve PR with CBR 36.0% (9/25); in patients without detectable TP53-mutation CBR is 47.4% (9/19). In this study, samuraciclib exhibits tolerable safety and PK is supportive of once-daily oral administration. Clinical activity in TNBC and HR+/HER2-breast cancer post-CDK4/6-inhibitor settings warrants further evaluation. Samuraciclib is a selective oral CDK7-inhibitor. A multi-modular, open-label Phase I study to evaluate safety and tolerability of samuraciclib in patients with advanced malignancies was designed (ClinicalTrials.gov: NCT03363893). Here we report results from dose escalation and 2 expansion cohorts: Module 1A dose escalation with paired biopsy cohort in advanced solid tumor patients, Module 1B-1 triple negative breast cancer (TNBC) monotherapy expansion, and Module 2A fulvestrant combination in HR+/HER2− breast cancer patients post-CDK4/6-inhibitor. Core study primary endpoints are safety and tolerability, and secondary endpoints are pharmacokinetics (PK), pharmacodynamic (PD) activity, and anti-tumor activity. Common adverse events are low grade nausea, vomiting, and diarrhea. Maximum tolerated dose is 360 mg once daily. PK demonstrates dose proportionality (120 mg-480 mg), a half-life of approximately 75 hours, and no fulvestrant interaction. In dose escalation, one partial response (PR) is identified with disease control rate of 53% (19/36) and reduction of phosphorylated RNA polymerase II, a substrate of CDK7, in circulating lymphocytes and tumor tissue. In TNBC expansion, one PR (duration 337 days) and clinical benefit rate at 24 weeks (CBR) of 20.0% (4/20) is achieved. In combination with fulvestrant, 3 patients achieve PR with CBR 36.0% (9/25); in patients without detectable TP53-mutation CBR is 47.4% (9/19). In this study, samuraciclib exhibits tolerable safety and PK is supportive of once-daily oral administration. Clinical activity in TNBC and HR+/HER2-breast cancer post-CDK4/6-inhibitor settings warrants further evaluation. Pre-clinical studies have demonstrated the anti-tumor activity of selective inhibitors of CDK7, including samuraciclib. Here the authors report the results from dose escalation and two expansion cohorts in patients with breast cancer of a multi-modular Phase I clinical trial of samuraciclib as anti-cancer treatment. Samuraciclib is a selective oral CDK7-inhibitor. A multi-modular, open-label Phase I study to evaluate safety and tolerability of samuraciclib in patients with advanced malignancies was designed (ClinicalTrials.gov: NCT03363893). Here we report results from dose escalation and 2 expansion cohorts: Module 1A dose escalation with paired biopsy cohort in advanced solid tumor patients, Module 1B-1 triple negative breast cancer (TNBC) monotherapy expansion, and Module 2A fulvestrant combination in HR+/HER2- breast cancer patients post-CDK4/6-inhibitor. Core study primary endpoints are safety and tolerability, and secondary endpoints are pharmacokinetics (PK), pharmacodynamic (PD) activity, and anti-tumor activity. Common adverse events are low grade nausea, vomiting, and diarrhea. Maximum tolerated dose is 360 mg once daily. PK demonstrates dose proportionality (120 mg-480 mg), a half-life of approximately 75 hours, and no fulvestrant interaction. In dose escalation, one partial response (PR) is identified with disease control rate of 53% (19/36) and reduction of phosphorylated RNA polymerase II, a substrate of CDK7, in circulating lymphocytes and tumor tissue. In TNBC expansion, one PR (duration 337 days) and clinical benefit rate at 24 weeks (CBR) of 20.0% (4/20) is achieved. In combination with fulvestrant, 3 patients achieve PR with CBR 36.0% (9/25); in patients without detectable TP53-mutation CBR is 47.4% (9/19). In this study, samuraciclib exhibits tolerable safety and PK is supportive of once-daily oral administration. Clinical activity in TNBC and HR+/HER2-breast cancer post-CDK4/6-inhibitor settings warrants further evaluation. Samuraciclib is a selective oral CDK7-inhibitor. A multi-modular, open-label Phase I study to evaluate safety and tolerability of samuraciclib in patients with advanced malignancies was designed (ClinicalTrials.gov: NCT03363893). Here we report results from dose escalation and 2 expansion cohorts: Module 1A dose escalation with paired biopsy cohort in advanced solid tumor patients, Module 1B-1 triple negative breast cancer (TNBC) monotherapy expansion, and Module 2A fulvestrant combination in HR+/HER2− breast cancer patients post-CDK4/6-inhibitor. Core study primary endpoints are safety and tolerability, and secondary endpoints are pharmacokinetics (PK), pharmacodynamic (PD) activity, and anti-tumor activity. Common adverse events are low grade nausea, vomiting, and diarrhea. Maximum tolerated dose is 360 mg once daily. PK demonstrates dose proportionality (120 mg-480 mg), a half-life of approximately 75 hours, and no fulvestrant interaction. In dose escalation, one partial response (PR) is identified with disease control rate of 53% (19/36) and reduction of phosphorylated RNA polymerase II, a substrate of CDK7, in circulating lymphocytes and tumor tissue. In TNBC expansion, one PR (duration 337 days) and clinical benefit rate at 24 weeks (CBR) of 20.0% (4/20) is achieved. In combination with fulvestrant, 3 patients achieve PR with CBR 36.0% (9/25); in patients without detectable TP53-mutation CBR is 47.4% (9/19). In this study, samuraciclib exhibits tolerable safety and PK is supportive of once-daily oral administration. Clinical activity in TNBC and HR+/HER2-breast cancer post-CDK4/6-inhibitor settings warrants further evaluation.Pre-clinical studies have demonstrated the anti-tumor activity of selective inhibitors of CDK7, including samuraciclib. Here the authors report the results from dose escalation and two expansion cohorts in patients with breast cancer of a multi-modular Phase I clinical trial of samuraciclib as anti-cancer treatment. Samuraciclib is a selective oral CDK7-inhibitor. A multi-modular, open-label Phase I study to evaluate safety and tolerability of samuraciclib in patients with advanced malignancies was designed (ClinicalTrials.gov: NCT03363893). Here we report results from dose escalation and 2 expansion cohorts: Module 1A dose escalation with paired biopsy cohort in advanced solid tumor patients, Module 1B-1 triple negative breast cancer (TNBC) monotherapy expansion, and Module 2A fulvestrant combination in HR+/HER2− breast cancer patients post-CDK4/6-inhibitor. Core study primary endpoints are safety and tolerability, and secondary endpoints are pharmacokinetics (PK), pharmacodynamic (PD) activity, and anti-tumor activity. Common adverse events are low grade nausea, vomiting, and diarrhea. Maximum tolerated dose is 360 mg once daily. PK demonstrates dose proportionality (120 mg-480 mg), a half-life of approximately 75 hours, and no fulvestrant interaction. In dose escalation, one partial response (PR) is identified with disease control rate of 53% (19/36) and reduction of phosphorylated RNA polymerase II, a substrate of CDK7, in circulating lymphocytes and tumor tissue. In TNBC expansion, one PR (duration 337 days) and clinical benefit rate at 24 weeks (CBR) of 20.0% (4/20) is achieved. In combination with fulvestrant, 3 patients achieve PR with CBR 36.0% (9/25); in patients without detectable TP53-mutation CBR is 47.4% (9/19). In this study, samuraciclib exhibits tolerable safety and PK is supportive of once-daily oral administration. Clinical activity in TNBC and HR+/HER2-breast cancer post-CDK4/6-inhibitor settings warrants further evaluation. Abstract Samuraciclib is a selective oral CDK7-inhibitor. A multi-modular, open-label Phase I study to evaluate safety and tolerability of samuraciclib in patients with advanced malignancies was designed (ClinicalTrials.gov: NCT03363893). Here we report results from dose escalation and 2 expansion cohorts: Module 1A dose escalation with paired biopsy cohort in advanced solid tumor patients, Module 1B-1 triple negative breast cancer (TNBC) monotherapy expansion, and Module 2A fulvestrant combination in HR+/HER2− breast cancer patients post-CDK4/6-inhibitor. Core study primary endpoints are safety and tolerability, and secondary endpoints are pharmacokinetics (PK), pharmacodynamic (PD) activity, and anti-tumor activity. Common adverse events are low grade nausea, vomiting, and diarrhea. Maximum tolerated dose is 360 mg once daily. PK demonstrates dose proportionality (120 mg-480 mg), a half-life of approximately 75 hours, and no fulvestrant interaction. In dose escalation, one partial response (PR) is identified with disease control rate of 53% (19/36) and reduction of phosphorylated RNA polymerase II, a substrate of CDK7, in circulating lymphocytes and tumor tissue. In TNBC expansion, one PR (duration 337 days) and clinical benefit rate at 24 weeks (CBR) of 20.0% (4/20) is achieved. In combination with fulvestrant, 3 patients achieve PR with CBR 36.0% (9/25); in patients without detectable TP53-mutation CBR is 47.4% (9/19). In this study, samuraciclib exhibits tolerable safety and PK is supportive of once-daily oral administration. Clinical activity in TNBC and HR+/HER2-breast cancer post-CDK4/6-inhibitor settings warrants further evaluation. Samuraciclib is a selective oral CDK7-inhibitor. A multi-modular, open-label Phase I study to evaluate safety and tolerability of samuraciclib in patients with advanced malignancies was designed (ClinicalTrials.gov: NCT03363893). Here we report results from dose escalation and 2 expansion cohorts: Module 1A dose escalation with paired biopsy cohort in advanced solid tumor patients, Module 1B-1 triple negative breast cancer (TNBC) monotherapy expansion, and Module 2A fulvestrant combination in HR+/HER2− breast cancer patients post-CDK4/6-inhibitor. Core study primary endpoints are safety and tolerability, and secondary endpoints are pharmacokinetics (PK), pharmacodynamic (PD) activity, and anti-tumor activity. Common adverse events are low grade nausea, vomiting, and diarrhea. Maximum tolerated dose is 360 mg once daily. PK demonstrates dose proportionality (120 mg-480 mg), a half-life of approximately 75 hours, and no fulvestrant interaction. In dose escalation, one partial response (PR) is identified with disease control rate of 53% (19/36) and reduction of phosphorylated RNA polymerase II, a substrate of CDK7, in circulating lymphocytes and tumor tissue. In TNBC expansion, one PR (duration 337 days) and clinical benefit rate at 24 weeks (CBR) of 20.0% (4/20) is achieved. In combination with fulvestrant, 3 patients achieve PR with CBR 36.0% (9/25); in patients without detectable TP53-mutation CBR is 47.4% (9/19). In this study, samuraciclib exhibits tolerable safety and PK is supportive of once-daily oral administration. Clinical activity in TNBC and HR+/HER2-breast cancer post-CDK4/6-inhibitor settings warrants further evaluation. Pre-clinical studies have demonstrated the anti-tumor activity of selective inhibitors of CDK7, including samuraciclib. Here the authors report the results from dose escalation and two expansion cohorts in patients with breast cancer of a multi-modular Phase I clinical trial of samuraciclib as anti-cancer treatment.
ArticleNumber	4444
Author	McIntosh, Stuart Bahl, Ashwani Jeselsohn, Rinath Gradishar, William Kenny, Laura Chap, Linnea I. Mitri, Zahi Richards, Paul Lord, Simon R. Ward, Patrick Baird, Richard D. Krebs, Matthew G. Clack, Glen Arkenau, Tobias Melear, Jason Mansi, Janine Palmieri, Carlo Howell, Sacha Chalasani, Pavani Sardesai, Sagar O’Shaughnessy, Joyce Coombes, R. C. Ali, Simak
Author_xml	– sequence: 1 givenname: R. C. orcidid: 0000-0002-4811-1100 surname: Coombes fullname: Coombes, R. C. organization: Imperial College, South Kensington – sequence: 2 givenname: Sacha surname: Howell fullname: Howell, Sacha organization: Division of Cancer Sciences, Faculty of Biology, Medicine and Health, The University of Manchester and The Christie NHS Foundation Trust, Manchester Academic Health Science Centre – sequence: 3 givenname: Simon R. orcidid: 0000-0001-7946-5609 surname: Lord fullname: Lord, Simon R. organization: Early Phase Clinical Trials Unit, Department of Oncology, University of Oxford – sequence: 4 givenname: Laura surname: Kenny fullname: Kenny, Laura organization: Imperial College, South Kensington – sequence: 5 givenname: Janine surname: Mansi fullname: Mansi, Janine organization: Guy’s and St Thomas’ NHS Foundation Trust – sequence: 6 givenname: Zahi orcidid: 0000-0001-8765-7723 surname: Mitri fullname: Mitri, Zahi organization: OHSU Knight Cancer Institute – sequence: 7 givenname: Carlo orcidid: 0000-0001-9496-2718 surname: Palmieri fullname: Palmieri, Carlo organization: University of Liverpool – sequence: 8 givenname: Linnea I. surname: Chap fullname: Chap, Linnea I. organization: University of California – sequence: 9 givenname: Paul surname: Richards fullname: Richards, Paul organization: Blue Ridge Cancer Center – sequence: 10 givenname: William orcidid: 0000-0002-2772-3140 surname: Gradishar fullname: Gradishar, William organization: Northwestern University – sequence: 11 givenname: Sagar surname: Sardesai fullname: Sardesai, Sagar organization: US Oncology Research, OHC – sequence: 12 givenname: Jason surname: Melear fullname: Melear, Jason organization: Baylor University Medical Center, Texas Oncology – sequence: 13 givenname: Joyce surname: O’Shaughnessy fullname: O’Shaughnessy, Joyce organization: Baylor University Medical Center, Texas Oncology – sequence: 14 givenname: Patrick orcidid: 0000-0002-7800-4840 surname: Ward fullname: Ward, Patrick organization: US Oncology Research, OHC – sequence: 15 givenname: Pavani surname: Chalasani fullname: Chalasani, Pavani organization: University of Arizona Cancer Center – sequence: 16 givenname: Tobias surname: Arkenau fullname: Arkenau, Tobias organization: Sarah Cannon Research Institute – sequence: 17 givenname: Richard D. surname: Baird fullname: Baird, Richard D. organization: Cancer Research UK Cambridge Centre – sequence: 18 givenname: Rinath orcidid: 0000-0001-7996-7529 surname: Jeselsohn fullname: Jeselsohn, Rinath organization: Dana-Farber Cancer Institute – sequence: 19 givenname: Simak orcidid: 0000-0002-1320-0816 surname: Ali fullname: Ali, Simak organization: Imperial College, South Kensington – sequence: 20 givenname: Glen surname: Clack fullname: Clack, Glen organization: Carrick Therapeutics – sequence: 21 givenname: Ashwani surname: Bahl fullname: Bahl, Ashwani organization: Carrick Therapeutics – sequence: 22 givenname: Stuart surname: McIntosh fullname: McIntosh, Stuart organization: Carrick Therapeutics – sequence: 23 givenname: Matthew G. orcidid: 0000-0001-7540-3064 surname: Krebs fullname: Krebs, Matthew G. email: matthew.krebs@manchester.ac.uk organization: Division of Cancer Sciences, Faculty of Biology, Medicine and Health, The University of Manchester and The Christie NHS Foundation Trust, Manchester Academic Health Science Centre
BackLink	https://www.ncbi.nlm.nih.gov/pubmed/37488191$$D View this record in MEDLINE/PubMed
BookMark	eNp9Uk1vEzEQXaEiWkL_AAdkiQuXBY_XG3tPCKV8RFSCA5ytWdubdbSxg73bkjN_HCcppe2hvnjG897zs2eeFyc-eFsUL4G-BVrJd4kDn4uSsqrklM6h3D0pzhjlUIJg1cmd-LQ4T2lN86oakJw_K04rwaWEBs6KPxchWWKTxgFHFzxBb4j9vUWf9pkOfYhjIs6Tba5bn-NrN_YEzRV6bQ1po8U0Er3P4h6H5HuPWXNJ0jiZHQkdGXtLFhdfRel871o3hkgSbqaI2unBtS-Kpx0OyZ7f7LPi56ePPxZfystvn5eLD5elrjmMpUVT65YaDhaqxtDOdtA1AKLCOUfJWC52KJCaprNgK1HnoKaaiY5roXk1K5ZHXRNwrbbRbTDuVECnDgchrhTGMVuyqgXeWta0EkTNW-zQUG44YiUEcFZD1np_1NpO7cYanX8m4nBP9H7Fu16twpXKzZvPIbdtVry5UYjh12TTqDYuaTsM6G2YkmKSgxRNTffGXz-ArsMUff6rA4rBnEmZUa_uWrr18q_ZGcCOAB1DStF2txCge19SHYdKZXfqMFRql0nyAUm78TAq-VlueJxaHakp3-NXNv63_QjrL_jC4qQ
CitedBy_id	crossref_primary_10_1186_s12964_024_01577_y crossref_primary_10_1016_j_ctrv_2025_102924 crossref_primary_10_3892_ijmm_2025_5564 crossref_primary_10_3390_cancers15194835 crossref_primary_10_3390_ijms26073438 crossref_primary_10_1080_14796694_2024_2419352 crossref_primary_10_3390_cancers17050774 crossref_primary_10_3390_molecules28227513 crossref_primary_10_1158_1078_0432_CCR_23_2975 crossref_primary_10_1038_s41586_024_08400_1 crossref_primary_10_1021_acs_jmedchem_5c01640 crossref_primary_10_1172_jci_insight_188051 crossref_primary_10_1002_advs_202413103 crossref_primary_10_1016_j_molmed_2024_09_004 crossref_primary_10_1016_j_gendis_2024_101435 crossref_primary_10_1016_j_drup_2024_101103 crossref_primary_10_1080_14728222_2025_2537412 crossref_primary_10_1210_endocr_bqaf127 crossref_primary_10_1016_j_annonc_2023_11_003 crossref_primary_10_1093_cvr_cvae084 crossref_primary_10_1038_s12276_025_01395_3 crossref_primary_10_1016_j_tranon_2025_102378 crossref_primary_10_1007_s11912_025_01689_9 crossref_primary_10_1177_17588359241282499 crossref_primary_10_1007_s12094_025_04044_3 crossref_primary_10_1016_j_canlet_2025_217453 crossref_primary_10_1126_scitranslmed_adq5091 crossref_primary_10_3390_jcm13123611 crossref_primary_10_1016_j_bbcan_2024_189174 crossref_primary_10_1038_s41416_024_02589_8 crossref_primary_10_1200_PO_24_00546 crossref_primary_10_1038_s44318_025_00554_6 crossref_primary_10_1007_s40265_024_02144_y crossref_primary_10_1007_s11030_024_10939_0 crossref_primary_10_1038_s41523_023_00578_3 crossref_primary_10_1186_s12885_024_12691_y
Cites_doi	10.1038/s41389-020-0232-1 10.1177/1947601912473308 10.1186/gb4184 10.1016/j.ccell.2014.10.019 10.1038/emboj.2010.337 10.1186/s13045-020-00926-x 10.1158/1538-7445.SABCS18-PD7-12 10.1158/1538-7445.SABCS17-P1-09-04 10.1200/JCO.2021.39.15_suppl.1000 10.1038/s41591-019-0380-z 10.1016/j.ejca.2008.10.026 10.1158/0008-5472.CAN-20-2245 10.1016/S1470-2045(21)00034-6 10.1016/S1097-2765(05)00004-3 10.1093/jnci/djaa087 10.1158/0008-5472.CAN-09-0301 10.1038/s41523-021-00222-y 10.4155/fmc-2019-0334 10.1186/s12964-022-00837-z 10.1038/nature13393 10.1016/j.jbc.2021.101162 10.1016/S0301-472X(01)00780-9 10.1016/j.cell.2014.10.024 10.1007/s10555-020-09885-8 10.1158/1535-7163.MCT-16-0847 10.1158/2159-8290.CD-19-0189 10.1002/onco.13609 10.1200/JCO.2020.38.15_suppl.TPS3662 10.1158/1538-7445.SABCS21-GS2-02 10.1158/0008-5472.CAN-16-2546 10.1158/1538-7445.SABCS18-GS3-08 10.1200/JCO.2021.39.15_suppl.1004
ContentType	Journal Article
Copyright	The Author(s) 2023 corrected publication 2023, 2025 2023. The Author(s). Copyright Nature Publishing Group 2023 The Author(s) 2023
Copyright_xml	– notice: The Author(s) 2023 corrected publication 2023, 2025 – notice: 2023. The Author(s). – notice: Copyright Nature Publishing Group 2023 – notice: The Author(s) 2023
DBID	C6C AAYXX CITATION CGR CUY CVF ECM EIF NPM 3V. 7QL 7QP 7QR 7SN 7SS 7ST 7T5 7T7 7TM 7TO 7X7 7XB 88E 8AO 8FD 8FE 8FG 8FH 8FI 8FJ 8FK ABUWG AEUYN AFKRA ARAPS AZQEC BBNVY BENPR BGLVJ BHPHI C1K CCPQU DWQXO FR3 FYUFA GHDGH GNUQQ H94 HCIFZ K9. LK8 M0S M1P M7P P5Z P62 P64 PHGZM PHGZT PIMPY PJZUB PKEHL PPXIY PQEST PQGLB PQQKQ PQUKI PRINS RC3 SOI 7X8 5PM DOA
DOI	10.1038/s41467-023-40061-y
DatabaseName	Springer Nature OA Free Journals CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed ProQuest Central (Corporate) Bacteriology Abstracts (Microbiology B) Calcium & Calcified Tissue Abstracts Chemoreception Abstracts Ecology Abstracts Entomology Abstracts (Full archive) Environment Abstracts Immunology Abstracts Industrial and Applied Microbiology Abstracts (Microbiology A) Nucleic Acids Abstracts Oncogenes and Growth Factors Abstracts Health & Medical Collection ProQuest Central (purchase pre-March 2016) Medical Database (Alumni Edition) ProQuest Pharma Collection Technology Research Database ProQuest SciTech Collection ProQuest Technology Collection ProQuest Natural Science Collection Hospital Premium Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Central One Sustainability ProQuest Central UK/Ireland Advanced Technologies & Computer Science Collection ProQuest Central Essentials Biological Science Collection ProQuest Central ProQuest Technology Collection Natural Science Collection Environmental Sciences and Pollution Management ProQuest One ProQuest Central Engineering Research Database Health Research Premium Collection Health Research Premium Collection (Alumni) ProQuest Central Student AIDS and Cancer Research Abstracts SciTech Premium Collection ProQuest Health & Medical Complete (Alumni) Biological Sciences ProQuest Health & Medical Collection Medical Database Biological Science Database Advanced Technologies & Aerospace Database ProQuest Advanced Technologies & Aerospace Collection Biotechnology and BioEngineering Abstracts ProQuest Central Premium ProQuest One Academic (New) Publicly Available Content Database ProQuest Health & Medical Research Collection ProQuest One Academic Middle East (New) One Health & Nursing ProQuest One Academic Eastern Edition (DO NOT USE) One Applied & Life Sciences ProQuest One Academic (retired) ProQuest One Academic UKI Edition ProQuest Central China Genetics Abstracts Environment Abstracts MEDLINE - Academic PubMed Central (Full Participant titles) DOAJ Directory of Open Access Journals
DatabaseTitle	CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) Publicly Available Content Database ProQuest Central Student Oncogenes and Growth Factors Abstracts ProQuest Advanced Technologies & Aerospace Collection ProQuest Central Essentials Nucleic Acids Abstracts SciTech Premium Collection ProQuest Central China Environmental Sciences and Pollution Management ProQuest One Applied & Life Sciences ProQuest One Sustainability Health Research Premium Collection Natural Science Collection Health & Medical Research Collection Biological Science Collection Chemoreception Abstracts Industrial and Applied Microbiology Abstracts (Microbiology A) ProQuest Central (New) ProQuest Medical Library (Alumni) Advanced Technologies & Aerospace Collection ProQuest Biological Science Collection ProQuest One Academic Eastern Edition ProQuest Hospital Collection ProQuest Technology Collection Health Research Premium Collection (Alumni) Biological Science Database Ecology Abstracts ProQuest Hospital Collection (Alumni) Biotechnology and BioEngineering Abstracts Entomology Abstracts ProQuest Health & Medical Complete ProQuest One Academic UKI Edition Engineering Research Database ProQuest One Academic Calcium & Calcified Tissue Abstracts ProQuest One Academic (New) Technology Collection Technology Research Database ProQuest One Academic Middle East (New) ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) ProQuest One Community College ProQuest One Health & Nursing ProQuest Natural Science Collection ProQuest Pharma Collection ProQuest Central ProQuest Health & Medical Research Collection Genetics Abstracts Health and Medicine Complete (Alumni Edition) ProQuest Central Korea Bacteriology Abstracts (Microbiology B) AIDS and Cancer Research Abstracts ProQuest SciTech Collection Advanced Technologies & Aerospace Database ProQuest Medical Library Immunology Abstracts Environment Abstracts ProQuest Central (Alumni) MEDLINE - Academic
DatabaseTitleList	MEDLINE - Academic MEDLINE Publicly Available Content Database CrossRef
Database_xml	– sequence: 1 dbid: DOA name: DOAJ Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 2 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 3 dbid: PIMPY name: Publicly Available Content Database (subscription) url: http://search.proquest.com/publiccontent sourceTypes: Aggregation Database
DeliveryMethod	fulltext_linktorsrc
Discipline	Biology
EISSN	2041-1723
EndPage	10
ExternalDocumentID	oai_doaj_org_article_b14be29b81754bafad04d4aa37714251 PMC10366102 37488191 10_1038_s41467_023_40061_y
Genre	Research Support, Non-U.S. Gov't Journal Article Clinical Trial, Phase I
GrantInformation_xml	– fundername: Carrick Therapeutics – fundername: Department of Health grantid: BRC-1215-20014 – fundername: Cancer Research UK grantid: C37/A18784 – fundername: Cancer Research UK grantid: C18616/A25153 – fundername: ;
GroupedDBID	--- 0R~ 39C 53G 5VS 70F 7X7 88E 8AO 8FE 8FG 8FH 8FI 8FJ AAHBH AAJSJ ABUWG ACGFO ACGFS ACIWK ACMJI ACPRK ADBBV ADFRT ADMLS ADRAZ AENEX AEUYN AFKRA AFRAH AHMBA AJTQC ALIPV ALMA_UNASSIGNED_HOLDINGS AMTXH AOIJS ARAPS ASPBG AVWKF AZFZN BBNVY BCNDV BENPR BGLVJ BHPHI BPHCQ BVXVI C6C CCPQU DIK EBLON EBS EE. EMOBN F5P FEDTE FYUFA GROUPED_DOAJ HCIFZ HMCUK HVGLF HYE HZ~ KQ8 LGEZI LK8 LOTEE M1P M48 M7P M~E NADUK NAO NXXTH O9- OK1 P2P P62 PHGZT PIMPY PQQKQ PROAC PSQYO RNS RNT RNTTT RPM SV3 TSG UKHRP AASML AAYXX AFFHD CITATION PHGZM PJZUB PPXIY PQGLB SNYQT CGR CUY CVF ECM EIF NPM 3V. 7QL 7QP 7QR 7SN 7SS 7ST 7T5 7T7 7TM 7TO 7XB 8FD 8FK AZQEC C1K DWQXO FR3 GNUQQ H94 K9. P64 PKEHL PQEST PQUKI PRINS RC3 SOI 7X8 PUEGO 5PM
ID	FETCH-LOGICAL-c541t-ead5cb0d41e139d0fef1f91173a64a822cb0fa7a0d9fe1e375d9f50c27f4c7c43
IEDL.DBID	M7P
ISICitedReferencesCount	47
ISICitedReferencesURI	http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=001036000300016&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
ISSN	2041-1723
IngestDate	Tue Oct 14 18:56:33 EDT 2025 Tue Nov 04 02:06:27 EST 2025 Thu Sep 04 16:00:47 EDT 2025 Tue Oct 07 07:10:57 EDT 2025 Mon Jul 21 05:59:22 EDT 2025 Sat Nov 29 08:12:43 EST 2025 Tue Nov 18 22:10:18 EST 2025 Sat Mar 08 01:11:05 EST 2025
IsDoiOpenAccess	true
IsOpenAccess	true
IsPeerReviewed	true
IsScholarly	true
Issue	1
Language	English
License	2023. The Author(s). Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
LinkModel	DirectLink
MergedId	FETCHMERGED-LOGICAL-c541t-ead5cb0d41e139d0fef1f91173a64a822cb0fa7a0d9fe1e375d9f50c27f4c7c43
Notes	ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23
ORCID	0000-0001-7996-7529 0000-0002-2772-3140 0000-0002-7800-4840 0000-0001-7946-5609 0000-0001-9496-2718 0000-0002-4811-1100 0000-0002-1320-0816 0000-0001-7540-3064 0000-0001-8765-7723
OpenAccessLink	https://www.proquest.com/docview/2841216288?pq-origsite=%requestingapplication%
PMID	37488191
PQID	2841216288
PQPubID	546298
PageCount	10
ParticipantIDs	doaj_primary_oai_doaj_org_article_b14be29b81754bafad04d4aa37714251 pubmedcentral_primary_oai_pubmedcentral_nih_gov_10366102 proquest_miscellaneous_2841879504 proquest_journals_2841216288 pubmed_primary_37488191 crossref_primary_10_1038_s41467_023_40061_y crossref_citationtrail_10_1038_s41467_023_40061_y springer_journals_10_1038_s41467_023_40061_y
PublicationCentury	2000
PublicationDate	2023-07-24
PublicationDateYYYYMMDD	2023-07-24
PublicationDate_xml	– month: 07 year: 2023 text: 2023-07-24 day: 24
PublicationDecade	2020
PublicationPlace	London
PublicationPlace_xml	– name: London – name: England
PublicationTitle	Nature communications
PublicationTitleAbbrev	Nat Commun
PublicationTitleAlternate	Nat Commun
PublicationYear	2023
Publisher	Nature Publishing Group UK Nature Publishing Group Nature Portfolio
Publisher_xml	– name: Nature Publishing Group UK – name: Nature Publishing Group – name: Nature Portfolio
References	E Chipumuro (40061_CR21) 2014; 159 CL Christensen (40061_CR22) 2014; 26 40061_CR25 D Chen (40061_CR4) 2000; 6 DG Rothwell (40061_CR33) 2019; 25 40061_CR29 RU Rasool (40061_CR18) 2019; 9 H Liu (40061_CR23) 2021; 81 S Ali (40061_CR10) 2009; 69 40061_CR9 MM Cook (40061_CR26) 2021; 26 B Li (40061_CR5) 2017; 77 RP Fisher (40061_CR2) 2012; 3 GP Sava (40061_CR6) 2020; 39 D Juric (40061_CR28) 2019; 79 M Wang (40061_CR7) 2020; 12 40061_CR14 N Kwiatkowski (40061_CR20) 2014; 511 40061_CR16 J Wang (40061_CR19) 2020; 13 M Malumbres (40061_CR1) 2014; 15 L Tang (40061_CR12) 2020; 9 GJ Lindeman (40061_CR15) 2021; 39 BM Webb (40061_CR13) 2021; 297 NS Datta (40061_CR17) 2002; 30 HS Rugo (40061_CR27) 2021; 22 EA Eisenhauer (40061_CR32) 2009; 45 M Cristofanilli (40061_CR30) 2021; 39 Y Wang (40061_CR11) 2022; 20 B O’Leary (40061_CR24) 2021; 113 JFR Robertson (40061_CR31) 2021; 7 H Patel (40061_CR8) 2018; 17 P Chymkowitch (40061_CR3) 2011; 30 37550302 - Nat Commun. 2023 Aug 7;14(1):4741. doi: 10.1038/s41467-023-40561-x. 40050276 - Nat Commun. 2025 Mar 6;16(1):2242. doi: 10.1038/s41467-025-57535-w.
References_xml	– volume: 9 year: 2020 ident: 40061_CR12 publication-title: Oncogenesis. doi: 10.1038/s41389-020-0232-1 – volume: 3 start-page: 731 year: 2012 ident: 40061_CR2 publication-title: Genes Cancer. doi: 10.1177/1947601912473308 – volume: 15 year: 2014 ident: 40061_CR1 publication-title: Genome Biol. doi: 10.1186/gb4184 – volume: 26 start-page: 909 year: 2014 ident: 40061_CR22 publication-title: Cancer Cell. doi: 10.1016/j.ccell.2014.10.019 – volume: 30 start-page: 468 year: 2011 ident: 40061_CR3 publication-title: EMBO J. doi: 10.1038/emboj.2010.337 – volume: 13 start-page: 99 year: 2020 ident: 40061_CR19 publication-title: J. Hematol. Oncol. doi: 10.1186/s13045-020-00926-x – ident: 40061_CR9 doi: 10.1158/1538-7445.SABCS18-PD7-12 – ident: 40061_CR14 doi: 10.1158/1538-7445.SABCS17-P1-09-04 – volume: 39 start-page: 15 year: 2021 ident: 40061_CR30 publication-title: J. Clin. Oncol. doi: 10.1200/JCO.2021.39.15_suppl.1000 – volume: 25 start-page: 738 year: 2019 ident: 40061_CR33 publication-title: Nat. Med. doi: 10.1038/s41591-019-0380-z – volume: 45 start-page: 228 year: 2009 ident: 40061_CR32 publication-title: Eur. J. Cancer. doi: 10.1016/j.ejca.2008.10.026 – volume: 81 start-page: 18 year: 2021 ident: 40061_CR23 publication-title: Cancer Res. doi: 10.1158/0008-5472.CAN-20-2245 – volume: 22 start-page: 489 year: 2021 ident: 40061_CR27 publication-title: Lancet Oncol. doi: 10.1016/S1470-2045(21)00034-6 – volume: 6 start-page: 127 year: 2000 ident: 40061_CR4 publication-title: Mol Cell. doi: 10.1016/S1097-2765(05)00004-3 – volume: 113 start-page: 309 year: 2021 ident: 40061_CR24 publication-title: J. Natl. Cancer Inst. doi: 10.1093/jnci/djaa087 – volume: 69 start-page: 6208 year: 2009 ident: 40061_CR10 publication-title: Cancer Res. doi: 10.1158/0008-5472.CAN-09-0301 – volume: 7 year: 2021 ident: 40061_CR31 publication-title: NPJ Breast Cancer doi: 10.1038/s41523-021-00222-y – volume: 12 start-page: 813 year: 2020 ident: 40061_CR7 publication-title: Future Med. Chem. doi: 10.4155/fmc-2019-0334 – volume: 20 year: 2022 ident: 40061_CR11 publication-title: Cell Commun. Signal. doi: 10.1186/s12964-022-00837-z – volume: 511 start-page: 616 year: 2014 ident: 40061_CR20 publication-title: Nature. doi: 10.1038/nature13393 – volume: 297 start-page: 101162 year: 2021 ident: 40061_CR13 publication-title: J. Biol. Chem. doi: 10.1016/j.jbc.2021.101162 – volume: 30 start-page: 158 year: 2002 ident: 40061_CR17 publication-title: Exp. Hematol. doi: 10.1016/S0301-472X(01)00780-9 – volume: 159 start-page: 1126 year: 2014 ident: 40061_CR21 publication-title: Cell. doi: 10.1016/j.cell.2014.10.024 – volume: 39 start-page: 805 year: 2020 ident: 40061_CR6 publication-title: Cancer Metastasis Rev. doi: 10.1007/s10555-020-09885-8 – volume: 17 start-page: 1156 year: 2018 ident: 40061_CR8 publication-title: Mol. Cancer Ther. doi: 10.1158/1535-7163.MCT-16-0847 – volume: 9 start-page: 1538 year: 2019 ident: 40061_CR18 publication-title: Cancer Discov. doi: 10.1158/2159-8290.CD-19-0189 – volume: 26 start-page: 101 year: 2021 ident: 40061_CR26 publication-title: Oncologist. doi: 10.1002/onco.13609 – ident: 40061_CR16 doi: 10.1200/JCO.2020.38.15_suppl.TPS3662 – ident: 40061_CR25 doi: 10.1158/1538-7445.SABCS21-GS2-02 – volume: 77 start-page: 3834 year: 2017 ident: 40061_CR5 publication-title: Cancer Res. doi: 10.1158/0008-5472.CAN-16-2546 – volume: 79 start-page: GS3 year: 2019 ident: 40061_CR28 publication-title: Cancer Res. doi: 10.1158/1538-7445.SABCS18-GS3-08 – ident: 40061_CR29 – volume: 39 start-page: 15 year: 2021 ident: 40061_CR15 publication-title: J. Clin. Oncol. doi: 10.1200/JCO.2021.39.15_suppl.1004 – reference: 37550302 - Nat Commun. 2023 Aug 7;14(1):4741. doi: 10.1038/s41467-023-40561-x. – reference: 40050276 - Nat Commun. 2025 Mar 6;16(1):2242. doi: 10.1038/s41467-025-57535-w.
SSID	ssj0000391844
Score	2.5885496
Snippet	Samuraciclib is a selective oral CDK7-inhibitor. A multi-modular, open-label Phase I study to evaluate safety and tolerability of samuraciclib in patients with... Abstract Samuraciclib is a selective oral CDK7-inhibitor. A multi-modular, open-label Phase I study to evaluate safety and tolerability of samuraciclib in...
SourceID	doaj pubmedcentral proquest pubmed crossref springer
SourceType	Open Website Open Access Repository Aggregation Database Index Database Enrichment Source Publisher
StartPage	4444
SubjectTerms	13/95 38/23 631/67/1059/153 692/308/153 692/4028/67/1347 Administration, Oral Anticancer properties Antitumor agents Biopsy Breast cancer Cancer therapies Cyclin-dependent kinase 4 Cyclin-Dependent Kinase Inhibitor Proteins Cyclin-Dependent Kinases Diarrhea Disease control DNA-directed RNA polymerase Enzyme Inhibitors ErbB-2 protein Fulvestrant Humanities and Social Sciences Humans Inhibitors Lymphocytes Malignancy Modules multidisciplinary Oral administration Patients Pharmacodynamics Pharmacokinetics RNA polymerase RNA polymerase II Safety Science Science (multidisciplinary) Solid tumors Substrates Triple Negative Breast Neoplasms Tumors Vomiting
SummonAdditionalLinks	– databaseName: DOAJ Directory of Open Access Journals dbid: DOA link: http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Lb9QwEB6hCiQuqLwDBRmJG0S1E2cdH6GlAoGqHgD1ZtmOrY0EWZTsVuyZP86Mk126PC_cktiRJvMe2_kG4Gkooq5snGFZostcVl7kuo4iLxraY4szLROQ9sd36vS0Pj_XZ5dafdGZsBEeeGTcoRPShUK7GuOcdDbahstGWlsqJVDfUuHDlb5UTCUfXGosXeT0lwwv68NBJp-AIQpLJgxi-XonEiXA_t9lmb8elvxpxzQFopN9uDFlkOzFSPlNuBK6W3Bt7Cm5vg3fjhdDYGFA3iemM9s1LHxFo6d1MUYNcfvlwNqOTZCqA6O1WLY5DMAcHVNfMk93Pc2z7GyOsY69YQmLli0iw6yRHR2_VXnbzVuHTqFng_286q1Hmlp3Bz6cvHp_9DqfOi3kvpJimaM6Vd7xRoqAGWHDY4giohtUpZ1JizkEDkarLG90DCKUqsKLivtCRemVl-Vd2OsWXbgPDD2ARvHwgMFX1kG7iiDnvaRftZ1uQgZiw3XjJxhy6obxyaTt8LI2o6QMSsokSZl1Bs-273wZQTj-OvslCXM7kwC00wNUKzOplfmXWmVwsFEFM1n1YDCUi0JQg-YMnmyH0R5pk8V2YbEa51ADdy4zuDdqzpYSgvqhAjmDekendkjdHenaecL8xm_FTIoXGTzfqN8Puv7Miwf_gxcP4XpBdsNVXsgD2Fv2q_AIrvqLZTv0j5PhfQdccjE4 priority: 102 providerName: Directory of Open Access Journals
Title	Dose escalation and expansion cohorts in patients with advanced breast cancer in a Phase I study of the CDK7-inhibitor samuraciclib
URI	https://link.springer.com/article/10.1038/s41467-023-40061-y https://www.ncbi.nlm.nih.gov/pubmed/37488191 https://www.proquest.com/docview/2841216288 https://www.proquest.com/docview/2841879504 https://pubmed.ncbi.nlm.nih.gov/PMC10366102 https://doaj.org/article/b14be29b81754bafad04d4aa37714251
Volume	14
WOSCitedRecordID	wos001036000300016&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
hasFullText	1
inHoldings	1
isFullTextHit
isPrint
journalDatabaseRights	– providerCode: PRVAON databaseName: DOAJ Directory of Open Access Journals customDbUrl: eissn: 2041-1723 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0000391844 issn: 2041-1723 databaseCode: DOA dateStart: 20150101 isFulltext: true titleUrlDefault: https://www.doaj.org/ providerName: Directory of Open Access Journals – providerCode: PRVHPJ databaseName: ROAD: Directory of Open Access Scholarly Resources customDbUrl: eissn: 2041-1723 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0000391844 issn: 2041-1723 databaseCode: M~E dateStart: 20100101 isFulltext: true titleUrlDefault: https://road.issn.org providerName: ISSN International Centre – providerCode: PRVPQU databaseName: Advanced Technologies & Aerospace Database customDbUrl: eissn: 2041-1723 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0000391844 issn: 2041-1723 databaseCode: P5Z dateStart: 20100101 isFulltext: true titleUrlDefault: https://search.proquest.com/hightechjournals providerName: ProQuest – providerCode: PRVPQU databaseName: Biological Science Database customDbUrl: eissn: 2041-1723 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0000391844 issn: 2041-1723 databaseCode: M7P dateStart: 20100101 isFulltext: true titleUrlDefault: http://search.proquest.com/biologicalscijournals providerName: ProQuest – providerCode: PRVPQU databaseName: Health & Medical Collection customDbUrl: eissn: 2041-1723 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0000391844 issn: 2041-1723 databaseCode: 7X7 dateStart: 20100101 isFulltext: true titleUrlDefault: https://search.proquest.com/healthcomplete providerName: ProQuest – providerCode: PRVPQU databaseName: ProQuest Central customDbUrl: eissn: 2041-1723 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0000391844 issn: 2041-1723 databaseCode: BENPR dateStart: 20100101 isFulltext: true titleUrlDefault: https://www.proquest.com/central providerName: ProQuest – providerCode: PRVPQU databaseName: Publicly Available Content Database (subscription) customDbUrl: eissn: 2041-1723 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0000391844 issn: 2041-1723 databaseCode: PIMPY dateStart: 20100101 isFulltext: true titleUrlDefault: http://search.proquest.com/publiccontent providerName: ProQuest
link	http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1Lj9MwEB6xuyBx4f0ILJWRuEG0ceLUyQmxL7ECqggBKlwix7FppN1kSVpEz_xxZpy0q_LYC5eoiR1p3BnPjGcm3wA8M6FNY2XHeCxJI1_EmvtpYrkflpRjs-NUOCDtT2_lZJJMp2k2BNy6oaxypROdoi4bTTHyPVSjPOTUHPfl-TefukZRdnVoobEFO4SSELrSvWwdYyH080SI4VuZIEr2OuE0AxoqPDihKfOXG_bIwfb_zdf8s2Tyt7ypM0fHN_93IbfgxuCIsle95NyGK6a-A9f61pTLu_DzsOkMMx2y0PGOqbpk5gfqDgqvMeqr2847VtVsQGbtGIV02aqmgBVU7T5nmu5amqdYNkOTyU6Yg7RljWXofLKDwzfSr-pZVaBuaVmnzhat0khTVdyDj8dHHw5e-0PDBl_Hgs99lMpYF0EpuEHHsgyssdyiNpWRGguFrggOWiVVUKbWcBPJGH_EgQ6lFVpqEd2H7bqpzUNgqEhSoVRg0IaLxKRFTMj1WtAX30VaGg_4im25HtDMqanGae6y6lGS96zOkdW5Y3W-9OD5-p3zHsvj0tn7JA3rmYTD7R407dd82NZ5wUVhwrRI0AsThbKqDESJdEdSctSG3IPdlRDkg3Lo8gsJ8ODpehi3NeVqVG2aRT-H-sAHwoMHveitKSHEIDpne5BsCOUGqZsjdTVz0OG4VnTIgtCDFyv5vaDr3__Fo8uX8Riuh7SlAumHYhe25-3CPIGr-vu86toRbMmpdNdkBDv7R5Ps_ciFPkZut-I1i7_gSHbyLvv8C8NRRmg
linkProvider	ProQuest
linkToHtml	http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMw1V1Lb9NAEB6VFFQuvB-GAosEJ7DqtdexfUAIGqpGSaMcCmpPZr3ebSyBXewEyJn_w29kxo9U4dFbD9yS7CYab775ZnZ2dgbgmXZN5EvTx21J5NnCV9yOQsNtN6UzNtOPRF1I-8M4mEzCo6NougE_u7swlFbZcWJN1GmhKEa-gzTKXU7NcV-ffrGpaxSdrnYtNBpYjPTyG27ZqlfDAf6_z113793h7r7ddhWwlS_43Mal81XipIJr9H5Sx2jDDap84Mm-kGgvcdDIQDppZDTXXuDjC99RbmCECpTw8HcvwaYgsPdgczo8mB6vojpUbz0Uor2d43jhTiVqLkLTiFs1NJ72cs0C1o0C_ubd_pmk-dtJbW0A967_b0t3A661rjZ70-jGTdjQ-S240jTfXN6GH4Oi0kxXCNIanUzmKdPfkR0pgMioc3A5r1iWs7b2bMUoaM26rAmWUD7_nCl6V9I8yaYzdArYkNVFe1lhGLrXbHcwCuwsn2UJsmfJKvl5UUqFMmXJHXh_IStwF3p5kev7wJAqIyGlo9FLEaGOEp9q8ytBd9qTKNUW8A4msWrrtVPbkE9xnTfghXEDrRihFdfQipcWvFh957SpVnLu7LeEvtVMqjRef1CUJ3FLXHHCRaLdKAnRzxSJNDJ1RIpye0HAUQW4Bdsd6OKW_qr4DHEWPF0NI3HRaZTMdbFo5lCne0dYcK-B-koSqolEkQQLwjUlWBN1fSTPZnVxdHxWdDkd14KXnb6cyfXvtXhw_mM8ga39w4NxPB5ORg_hqkvq7AS2K7ahNy8X-hFcVl_nWVU-bhmBwceL1qRfgwOgGQ
linkToPdf	http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMw1V1Lj9MwEB4ty0NceD8CCxgJThA1Tpw6PiAEWyqqrqoeAK24BMexaSRIlqQFeuZf8esYO0lX5bG3PXBra7eauN98Mx6PZwAe6dCIWJohbktE5LNYUV8khvphbs_YzFAwV0j73QGfzZLDQzHfgZ_9XRibVtlzoiPqvFI2Rj5AGqUhtc1xB6ZLi5iPxs-Pvvi2g5Q9ae3babQQmer1N9y-Nc8mI_yvH4fh-NWb_dd-12HAVzGjSx-XMVZZkDOq0RPKA6MNNaj-PJJDJtF24qCRXAa5MJrqiMf4Ig5UyA1TXLEIf_cMnOW4x7TphPP4_Sa-YyuvJ4x193SCKBk0zLESGknctKEZ9ddbttC1DPibn_tnuuZvZ7bOFI4v_8-LeAUudQ44edFqzFXY0eU1ON-25Fxfhx-jqtFENwhdh1kiy5zo78iZNqxIbD_hetmQoiRdRdqG2FA26XMpSGaz_JdE2Xe1nSfJfIGuApkQV8qXVIag0032R1PuF-WiyJBTa9LIz6taKpSpyG7A21NZgZuwW1alvg0ECVQwKQONvgtLtMhiW7FfMXvTPRO59oD2kElVV8XdNhP5lLpsgihJW5ilCLPUwSxde_Bk852jtobJibNfWiRuZtr64-6Dqv6YdnSWZpRlOhRZgt4ny6SRecBylDvinKIVoB7s9QBMO1Js0mP0efBwM4x0Zs-oZKmrVTsn4SIOmAe3WthvJLGVkmx8wYNkSyG2RN0eKYuFK5mOz4qOaBB68LTXnWO5_r0Wd05-jAdwAdUnPZjMpnfhYmg1O-B-yPZgd1mv9D04p74ui6a-76iBwIfTVqNfOqmnfA
openUrl	ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Dose+escalation+and+expansion+cohorts+in+patients+with+advanced+breast+cancer+in+a+Phase+I+study+of+the+CDK7-inhibitor+samuraciclib&rft.jtitle=Nature+communications&rft.au=Coombes%2C+R+C&rft.au=Howell%2C+Sacha&rft.au=Lord%2C+Simon+R&rft.au=Kenny%2C+Laura&rft.date=2023-07-24&rft.issn=2041-1723&rft.eissn=2041-1723&rft.volume=14&rft.issue=1&rft.spage=4444&rft_id=info:doi/10.1038%2Fs41467-023-40061-y&rft.externalDBID=NO_FULL_TEXT
thumbnail_l	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2041-1723&client=summon
thumbnail_m	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2041-1723&client=summon
thumbnail_s	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2041-1723&client=summon